CFO transition
Stark Focus Group, Inc. CFO transition: Matthew Szot to succeed John Lipman
Stark Focus Group, Inc. reported in a Form 8-K filed September 25, 2026 that Matthew Szot will succeed John Lipman as Chief Financial Officer, effective October 8, 2026.
In the filing's words
On September 21, 2026, the Board of Directors (the “ Board ”) of Stark Focus Group, Inc. (the “ Company ”) unanimously approved the appointment of Matthew Szot to be the Company’s new Chief Financial Officer, effective on October 8, 2026 (the “ Effective Date ”).
Verbatim from sec.gov, Item 5.02. We quote departures; we do not characterize them.
| Company | Stark Focus Group, Inc. |
|---|---|
| Event | Transition |
| Incoming | Matthew Szot |
| Outgoing | John Lipman |
| Title in the filing | Chief Financial Officer |
| Effective | October 8, 2026 |
| 8-K filed | September 25, 2026 |
| Internal promotion | No |
| Prior role (per filing) | Chief Financial Officer, Cadrenal Therapeutics, Inc. |
| SEC CIK | 0001794942 |
Stark Focus Group, Inc. reported this change in a Form 8-K, Item 5.02, filed September 25, 2026. The filing's own words are quoted above.
Other records naming Matthew Szot
1The incoming officer on this record, matched by name. Career line.
2026-03-31 · 10-K signature
Matthew Szot signed Cadrenal Therapeutics, Inc.'s annual report as Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)
Also filed in September 2026
Other CFO moves on the record that month. All moves.
6 weeks ago· 2026-09-30InterimACI
Albertsons Companies, Inc. names Cody Perdue interim CFO
6 weeks ago· 2026-09-30DepartureALDA
Atlantica Inc. discloses CFO departure: Shelley Goff
6 weeks ago· 2026-09-30TransitionCARL
Carlsmed, Inc. CFO transition: Richard Heppenstall to succeed Leo Greenstein
6 weeks ago· 2026-09-30AppointmentLEVI
Levi Strauss & Co. appoints John Vandemore as CFO
6 weeks ago· 2026-09-30DeparturePTPI
Petros Pharmaceuticals, Inc. discloses CFO departure: Robert Weinstein
6 weeks ago· 2026-09-30DepartureTCRX
TScan Therapeutics, Inc. discloses CFO departure: Jason A. Amello
Sources
- sec.gov · SEC filing, Item 5.02 · accessed 2026-09-26
Something wrong about Matthew Szot? Send a correction with the primary source.